Compare Amgen, Inc. (AMGN) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Invesco Solar ETF — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Invesco Solar ETF trades at $53.29. The key difference: Amgen, Inc. pays a 2.42% dividend while Invesco Solar ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | TAN | |
|---|---|---|
Market Cap | $225.71B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $73.95 |
52-Week Low | $271.18 | $36.62 |
Enterprise Value | $269.02B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TAN trades at $52.75, up 2.93% today amid positive solar sector news. Technical indicators are bearish overall, with moving averages signaling caution and RSI-6 suggesting overbought conditions. Recent tariffs on imported solar products have boosted sentiment, but the ETF faces headwinds from high volatility and regulatory uncertainty.
The outlook is mixed: supportive policies may drive growth, yet valuation concerns and interest rate sensitivity pose risks. Investors should weigh exposure to utility-scale solar growth against sector volatility and top-heavy holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
